Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Anvumetostat With or Without Chemoimmunotherapy in MTAP-deleted Advanced NSCLC (Japan, Subprotocol A)
jRCT2051240116Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of anvumetostat in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Amgen. Primary endpoints: Number of participants experiencing dose limiting toxicities (DLT), Number of participants experiencing treatment-emergent adverse events (TEAE) and 1 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240116.